<DOC>
	<DOC>NCT00611897</DOC>
	<brief_summary>This study tests the hypothesis that extrasynaptic mechanisms are critically linked with cognitive effects of NMDA antagonism as evidenced by event-related potentials (ERPs) in healthy humans.</brief_summary>
	<brief_title>N-acetylcysteine and NMDA Antagonist Interactions</brief_title>
	<detailed_description />
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Ages of 2145 years from all ethnic backgrounds. Male or female. Written informed consent. Exclusion criteria DSMIV diagnosis for a psychotic, depressive or anxiety disorder. A history of significant medical/neurological disease such as cardiac, thyroid, renal, hepatic abnormality, seizure disorder. Unstable medical condition based on EKG, vital signs, physical examination and laboratory workup (CBC with differential, SMA7, LFTs, TFTs, UA, Utox, Urine pregnancy test) . History of severe allergies or multiple adverse drug reactions. Any medication that in the opinion of the PI could interfere with either the safety of the study and/or the outcome measures. Any other conditions which in the opinion of the investigator would preclude participation in the study. History of major psychiatric disorder in first degree relatives. Current substance abuse/dependency determined by urine toxicology. Current treatment with medications with psychotropic effects. Treatment with benzodiazepines within one week prior to testing. Current pregnancy, unsatisfactory birth control method report for females. Education &lt; 10th grade. IQ &lt; 70, MR as determined by Wechsler Abbreviated Scale of Intelligence. NonEnglish speaking.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>NMDA</keyword>
	<keyword>glutamate</keyword>
	<keyword>N-acetylcysteine</keyword>
	<keyword>P3</keyword>
</DOC>